Abstract
Cancer drug discovery is one of the most rapidly changing areas of pharmaceutical research. Uncontrolled proliferation is a hallmark of cancer cells. Over the past two decades, it has become increasingly clear that in many human cancers, hyperactivity of Cyclin Dependent Kinases (CDKs) is one of the mechanisms underlying the physiological hyper-proliferation. CDKs are serine/threonine protein kinases, which play an important role in cell-cycle regulation. Their sequential activation ensures, the correct timing and ordering of events required for cell cycle progression. Therefore, inhibition of CDKs, through the insertion of small molecules into its ATP binding pocket has emerged as a potential therapy method for cancers. Consequently, a number of small molecules with CDK inhibitory properties have been developed. Many of these have been evaluated as potent inhibitors and some are currently in clinical-trials for various types of cancer. This review reports various CDK inhibitors, natural as well as small molecules, along with their reported activities for various CDKs. It will highlight the potential for the development of novel anti-cancer molecules.
Keywords: Cyclin dependent kinase, CKIs, small molecule inhibitors, anticancer agents, cell cycle, apoptosis
Current Cancer Drug Targets
Title: Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment
Volume: 8 Issue: 1
Author(s): P. Sapra Sharma, R. Sharma and R. Tyagi
Affiliation:
Keywords: Cyclin dependent kinase, CKIs, small molecule inhibitors, anticancer agents, cell cycle, apoptosis
Abstract: Cancer drug discovery is one of the most rapidly changing areas of pharmaceutical research. Uncontrolled proliferation is a hallmark of cancer cells. Over the past two decades, it has become increasingly clear that in many human cancers, hyperactivity of Cyclin Dependent Kinases (CDKs) is one of the mechanisms underlying the physiological hyper-proliferation. CDKs are serine/threonine protein kinases, which play an important role in cell-cycle regulation. Their sequential activation ensures, the correct timing and ordering of events required for cell cycle progression. Therefore, inhibition of CDKs, through the insertion of small molecules into its ATP binding pocket has emerged as a potential therapy method for cancers. Consequently, a number of small molecules with CDK inhibitory properties have been developed. Many of these have been evaluated as potent inhibitors and some are currently in clinical-trials for various types of cancer. This review reports various CDK inhibitors, natural as well as small molecules, along with their reported activities for various CDKs. It will highlight the potential for the development of novel anti-cancer molecules.
Export Options
About this article
Cite this article as:
Sharma Sapra P., Sharma R. and Tyagi R., Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment, Current Cancer Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/156800908783497131
DOI https://dx.doi.org/10.2174/156800908783497131 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glycans in Magnetic Resonance Imaging: Determinants of Relaxivity to Smart Agents, and Potential Applications in Biomedicine
Current Medicinal Chemistry Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design PET Tracers Based on 86Y
Current Radiopharmaceuticals Intracellular Signaling Triggered by Formyl-Peptide Receptors in Nonphagocytic Cells
Current Signal Transduction Therapy Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Vector Delivery Methods and Targeting Strategies for Gene Therapy of Brain Tumors
Current Gene Therapy Prospects of miRNA-Based Therapy for Pancreatic Cancer
Current Drug Targets Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design The Multidrug Resistance Mechanisms and their Interactions with the Radiopharmaceutical Probes Used for an In Vivo Detection
Current Drug Metabolism An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity
Current Cancer Drug Targets Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging
Current Protein & Peptide Science Microglia in Alzheimer's Disease: The Good, the Bad and the Ugly
Current Alzheimer Research Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease
Current Neuropharmacology Saponins in Tumor Therapy
Mini-Reviews in Medicinal Chemistry Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy Recent Development in the Fabrication of Collagen Scaffolds for Tissue Engineering Applications: A Review
Current Pharmaceutical Biotechnology Mesenchymal stem cell therapy for inflammatory bowel diseases: promise and challenge
Current Stem Cell Research & Therapy Polyphenols and Neuroprotection against Ischemia and Neurodegeneration
Mini-Reviews in Medicinal Chemistry APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology